Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1025 of 1048 entries
View as:

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05303090 Org: User:
Start: 03/31/22 End: 04/23/24 Due: 04/23/25

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06798506 Org: User:
Start: 02/15/25 End: 05/15/27 Due: 05/15/28

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03254654 Org: User:
Start: 08/16/17 End: 08/01/21 Due: 08/01/22

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05989425 Org: User:
Start: 08/04/23 End: 08/04/26 Due: 08/04/27

Study of Weekly DCF to Treat Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00568971 Org: User:
Start: 04/30/07 End: 06/30/08 Due: 06/30/09

TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC

Phase: N/A Priority: Normal
NCT ID: NCT06990620 Org: User:
Start: 06/30/25 End: 12/31/27 Due: 12/31/28

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06470672 Org: User:
Start: 12/31/24 End: 07/31/26 Due: 07/31/27

A Study of the Intervention of Time-restricted Eating in High-risk Populations of GDM

Phase: N/A Priority: Normal
NCT ID: NCT06431997 Org: User:
Start: 04/17/24 End: 12/31/26 Due: 12/31/27

A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06903325 Org: User:
Start: 10/01/23 End: 10/31/27 Due: 10/31/28

PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-II

Phase: N/A Priority: Normal
NCT ID: NCT06001099 Org: User:
Start: 02/22/23 End: 12/31/24 Due: 12/31/25

Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations

Phase: N/A Priority: Normal
NCT ID: NCT02628613 Org: User:
Start: 12/31/15 End: 02/28/19 Due: 02/28/20

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Phase: N/A Priority: Normal
NCT ID: NCT05255406 Org: User:
Start: 12/09/21 End: 12/31/24 Due: 12/31/25

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Phase: N/A Priority: Normal
NCT ID: NCT04127019 Org: User:
Start: 06/01/10 End: 06/15/17 Due: 06/15/18

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05582499 Org: User:
Start: 11/01/22 End: 09/30/25 Due: 09/30/26

A Longitudinal Study of the Trajectory of Financial Toxicity and Its Relationship With Symptom Burden in Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT05964816 Org: User:
Start: 11/16/22 End: 03/31/24 Due: 03/31/25

S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03668366 Org: User:
Start: 08/01/13 End: 08/01/20 Due: 08/01/21

Cohort of Twin Pregnancy and the Offspring

Phase: N/A Priority: Normal
NCT ID: NCT05727085 Org: User:
Start: 10/15/23 End: 06/15/29 Due: 06/15/30

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase: N/A Priority: Normal
NCT ID: NCT05891093 Org: User:
Start: 06/01/23 End: 05/31/31 Due: 05/31/32

A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01591135 Org: User:
Start: 04/30/12 End: 08/31/18 Due: 08/31/19

Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06369181 Org: User:
Start: 01/01/21 End: 12/31/28 Due: 12/31/29

Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05863260 Org: User:
Start: 11/09/20 End: 12/31/24 Due: 12/31/25

Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03380468 Org: User:
Start: 01/01/18 End: 12/31/25 Due: 12/31/26

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01192243 Org: User:
Start: 12/31/09 End: - Due: -

WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06243003 Org: User:
Start: 01/15/24 End: 12/31/26 Due: 12/31/27

A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01391572 Org: User:
Start: 04/30/11 End: - Due: -